Bound Therapeutics is developing next-generation RNA therapies for aggressive cancers and rare diseases using its AI-driven Magic Bullet Designer™ platform. By combining targeted delivery with precision peptide engineering, Bound is creating antisense therapeutics with improved efficacy, safety, and personalization—aiming to transform treatment for underserved patient populations.
Lead Program & Pipeline
-
Lead molecule: Antisense oligonucleotide targeting aggressive cancers, including triple-negative breast cancer (TNBC)
-
Developed with Magic Bullet Designer™ (MBD), a proprietary AI-driven RNA delivery platform
-
Pipeline expansion planned for lung, colon cancers, and genetic disorders
-
Future programs to target inflammatory and neurodegenerative diseases
Technology Differentiators
-
Cancer-specific RNA delivery minimizes toxicity and preserves immune function
-
Uses peptide ligand–based targeting for tissue precision
-
Combines antisense RNA analogs with AI/ML optimization
-
Enables personalized treatment through companion diagnostics and biomarker integration
Stage & Investment
-
Stage: Preclinical
-
Funding Raised: <$500K
-
IP: One issued patent; one PCT filed in 2024
-
Current Funding Goal: $3–4M seed round to complete IND-enabling studies and scale manufacturing
-
Collaborators: Charles River, PeptiStar, Millipore Sigma, WuXi AppTec, Eureka Biotechnology, Riken Genesis
What's Next
-
Initiate IND-enabling studies and preclinical safety evaluation in two species
-
Complete IND submission package for FDA
-
Engage in regulatory consultations (Pre-IND, Orphan Drug, Fast Track designation)
-
Raise Series A post-IND to begin Phase I trials
Leadership
Crystal Jin, PhD
CEO & Co-founder
Eric Wickstrom, PhD
CSO & Co-founder